Table 4 Odds ratios (95% confidence intervals (CI)) for a doubling of baseline sex hormone levels in the randomized placebo and active treatment groups of the Women’s Health Initiative postmenopausal hormone therapy trials

CEE + MPA trial*

Estradiol

2.00 (1.24, 3.21)

0.96 (0.66, 1.40)

276/314

Bioavailable estradiol

1.98 (1.27, 3.07)

1.01 (0.72, 1.43)

265/299

Estrone

1.77 (1.15, 2.73)

1.07 (0.74, 1.56)

273/313

Estrone sulfate

1.18 (0.78, 1.80)

1.08 (0.78, 1.49)

245/287

SHBG*

0.75 (0.51, 1.12)

1.14 (0.82, 1.59)

274/323

CEE trial*

Estradiol

1.50 (0.85, 2.65)

1.31 (0.88, 1.97)

172/207

Bioavailable estradiol

1.69 (0.99, 2.87)

1.58 (1.06, 2.36)

169/203

Estrone

1.28 (0.78, 2.10)

1.31 (0.83, 2.07)

186/216

Estrone sulfate

1.58 (0.91, 2.73)

1.05 (0.65, 1.70)

160/184

SHBG*

0.65 (0.39, 1.08)

0.61 (0.40, 0.92)

178/208